- Home
- STRW vs MIST Comparison
STRW vs MIST Comparison
Compare STRW & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- MIST
- Stock Information
- Founded
- STRW 2015
- MIST 2003
- Country
- STRW United States
- MIST Canada
- Employees
- STRW N/A
- MIST N/A
- Industry
- STRW Real Estate Investment Trusts
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- STRW Real Estate
- MIST Health Care
- Exchange
- STRW Nasdaq
- MIST Nasdaq
- Market Cap
- STRW 151.1M
- MIST 163.2M
- IPO Year
- STRW N/A
- MIST N/A
- Fundamental
- Price
- STRW $12.03
- MIST $2.00
- Analyst Decision
- STRW Strong Buy
- MIST Strong Buy
- Analyst Count
- STRW 4
- MIST 3
- Target Price
- STRW $12.72
- MIST $6.33
- AVG Volume (30 Days)
- STRW 27.7K
- MIST 1.7M
- Earning Date
- STRW 11-06-2025
- MIST 11-12-2025
- Dividend Yield
- STRW 5.32%
- MIST N/A
- EPS Growth
- STRW 19.41
- MIST N/A
- EPS
- STRW 0.61
- MIST N/A
- Revenue
- STRW $145,392,000.00
- MIST N/A
- Revenue This Year
- STRW $33.39
- MIST N/A
- Revenue Next Year
- STRW $5.21
- MIST N/A
- P/E Ratio
- STRW $19.80
- MIST N/A
- Revenue Growth
- STRW 29.76
- MIST N/A
- 52 Week Low
- STRW $8.70
- MIST $0.63
- 52 Week High
- STRW $12.84
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- STRW 55.90
- MIST 57.15
- Support Level
- STRW $11.53
- MIST $1.85
- Resistance Level
- STRW $12.28
- MIST $1.99
- Average True Range (ATR)
- STRW 0.33
- MIST 0.12
- MACD
- STRW 0.08
- MIST 0.01
- Stochastic Oscillator
- STRW 78.45
- MIST 82.14
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).